



[243] Attorney Docket No. : AGI-127US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David A. Brown and Daniel B. Yarosh
Serial No. : 10/070,466
Filed : March 7, 2002
For : COMPOSITIONS AND METHODS FOR
MODIFICATION OF SKIN LIPID CONTENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that the following correspondence attached hereto is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

1. Information Disclosure Statement (1 page)
2. Modified 1449 Form (6 pages)
3. Cited References (56 references)
4. Certificate of Mailing (1 page; this page)
5. Return Receipt Postcard (1 card)

RECEIVED

FEB 24 2004

Date Mailed:

September 30, 2003

9/30/03

Date Signed

Maurice M. Klee

Maurice M. Klee, Ph.D.



[243] Attorney Docket No. : AGI-127US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David A. Brown and Daniel B. Yarosh
Serial No. : 10/070,466
Filed : March 7, 2002
For : COMPOSITIONS AND METHODS FOR
MODIFICATION OF SKIN LIPID CONTENT

RECEIVED

FEB 24 2004

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 37 CFR §1.97(b)(3), applicants wish to call the Examiner's attention to the references listed on the Modified 1449 Form submitted herewith. Copies of these references are enclosed.

The foregoing references are being submitted prior to the mailing date of a first substantive Office Action for this application and thus no fee under 37 CFR §1.17(p) is believed to be due for this submission. However, if a fee is required, applicants request that the fee be charged to Deposit Account No. 11-1158.

The Examiner is respectfully requested to initial a copy of the Modified 1449 Form and return it to applicants to indicate consideration of the references listed thereon in connection with the prosecution of this application.


Respectfully submitted,

Date:

9/30/03

Maurice M. Klee

Maurice M. Klee, Ph.D.
Reg. No. 30,399
Attorney for Applicant
1951 Burr Street
Fairfield, CT 06824
(203) 255-1400



[248] Attorney Docket No. : AGI-127US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
FEB 24 2004


Applicant : David A. Brown and Daniel B. Yarosh
Serial No. : 10/070,466
Filed : March 7, 2002
For : COMPOSITIONS AND METHODS FOR
MODIFICATION OF SKIN LIPID CONTENT
Examiner : R. Cook
Group : 1614

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56, 37 CFR §1.97(c) and 37 CFR §1.97(e)(2), applicants wish to call the Examiner's attention to References 57-58 listed on the Supplemental Modified 1449 Form submitted herewith. Copies of these references are enclosed.

The undersigned certifies that Reference 57 was not cited in any communication from a foreign patent office in a counterpart foreign application or known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement. In particular, Reference 57 is a full copy of the Fontanel et al. reference cited in the October 8, 2003 Office Action for this application. The undersigned attorney obtained this full copy within the last three months. References 58 and 59 are computer-generated English language translations of Reference 57, also obtained within the last three months.

The Examiner is respectfully requested to initial a copy of the Supplemental Modified 1449 Form and return it to applicants to indicate



consideration of the references listed thereon in connection with the prosecution of this application.

Respectfully submitted,

Date: 2/9/04 Maurice M. Klee

Maurice M. Klee, Ph.D.

Reg. No. 30,399

Attorney for Applicant

1951 Burr Street

Fairfield, CT 06824

(203) 255-1400

RECEIVED
FEB 24 2004



[243] Attorney Docket No. : AGI-127US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David A. Brown and Daniel B. Yarosh
Serial No. : 10/070,466
Filed : March 7, 2002
For : COMPOSITIONS AND METHODS FOR
MODIFICATION OF SKIN LIPID CONTENT

MODIFIED 1449 FORM

RECEIVED

U.S. PATENT DOCUMENTS

FEB 24 2004

<u>Examiner Initial</u>		<u>Document Number</u>	<u>Issue Date</u>	<u>Name</u>
_____	1.	3,903,089	9/1975	Vanstone
_____	2.	4,530,934	7/1985	Clavenna et al.
_____	3.	4,857,554	8/1989	Kallimanis
_____	4.	5,051,449	9/1991	Kligman
_____	5.	5,075,340	12/1991	Barua et al.
_____	6.	5,314,877	5/1994	Suzuki et al.
_____	7.	5,556,844	9/1996	Reichert et al.
_____	8.	5,624,909	4/1997	Rao et al.
_____	9.	5,723,139	3/1998	Granger et al.
_____	10.	5,837,224	11/1998	Voorhees et al.
_____	11.	RE 36,068	1/1999	Kligman

FOREIGN PATENT DOCUMENTS

<u>Examiner Initial</u>		<u>Document Number</u>	<u>Date</u>	<u>Country</u>
_____	12.	11-5727 with attached English abstract	1/1999	JP

OTHER ART

<u>Examiner Initial</u>		
_____	13.	Abraham et al., 1985, "Linoleate-rich acylglucosylceramides of pig epidermis: structure determination by proton magnetic resonance," <u>J. Lipid Res.</u> , 26:761-766.
_____	14.	Baek et al., 1997, "Intracellular Ca ²⁺ release mediates ursolic acid-induced apoptosis in human leukemic HL-60 cells," <u>Int. J. Cancer</u> , 73:725-728.
_____	15.	Balanehru et al., 1991, "Protective effect of oleanolic acid and ursolic acid against lipid peroxidation," <u>Biochem. Int.</u> , 24:981-990.
_____	16.	Bligh et al., 1959, "A rapid method of total lipid extraction and purification," <u>Canad. J. Biochem. Physiol.</u> , 37:911-917.
_____	17.	Bontè et al., 1997, "Existence of a lipid gradient in the upper stratum corneum and its possible biological significance," <u>Arch. Dermatol. Res.</u> , 289:78-82.
_____	18.	Brincat et al., 1987, "Skin collagen changes in post-menopausal women receiving oestradiol gel," <u>Maturitas</u> , 9:1-5.
_____	19.	Cha et al., 1996, "Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells," <u>Cancer Res.</u> , 56:2281-84.

- _____ 20. Cha et al., 1998, "Urosolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells," Oncogene, 16:771-778.
- _____ 21. Cox et al., 1986, "Variations in lipids in different layers of procine epidermis," J. Invest. Dermatol., 87:741-744.
- _____ 22. Database DRUGU on STN, Derwent Information Ltd., No. 1996-25548, SANG, T. K. "The effect of ursolic acid and all-trans-retinoic acid on ultraviolet A radiation induced elastin mRNA expression in cultured human dermal fibroblast." abstract, J. Invest. Dermatol., 106(4), 836, 1996.
- _____ 23. Database DRUGU on STN, Derwent Information Ltd., KIM, S.T. et al. Accession No. 23729, "The effect of all trans-retinoic acid, ursolic acid, ginseng, and aloe extract on ultraviolet A radiation induced collagenase mRNA expression in culture human dermal fibroblast," abstract, J. Invest. Dermatol., 104(4), 621, 1995.
- _____ 24. Database DRUGU on STN, Derwent Information Ltd., SEKI, T. et al., Accession 28819. "Effect of Some Alkaloids and Flavonoids and Triterpenoids, Contents of Japanese-Chinese Traditional Herbal Medicines, on the Lipogenesis of Sebaceous Glands," abstract, Sking Pharmacol. 6(1), 56-60, 1993.
- _____ 25. Downing et al., "Lipids of the epidermis and the sebaceous glands," Dermatology in General Medicine, T. Fitzpatrick et al. editors, McGraw-Hill, New York, 1993, 210-221.
- _____ 26. Es-Saady et al., 1996, "MCF-7 cell cycle arrested at G1 through ursolic acid, and increased reduction of tetrazolium salts," Anticancer Res., 16:481-486.

- _____ 27. Es-Saady et al., 1996, "Inhibitory effect of ursolic acid on B16 proliferation through cell cycle arrest," Cancer Lett., 106:193-197.
- _____ 28. Farina et al., 1998, "Synthesis and anti-ulcer activity of new derivatives of glycyrrhetic, oleanolic and ursolic acids," Il Farmaco, 53: 22-32.
- _____ 29. Griffiths et al., 1993, "Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid)," New Engl. J. Med., 329:530-5.
- _____ 30. Griffiths, C. E. M., 1999, "Drug treatment of photoaged skin," Drugs & Aging, 14:289-301.
- _____ 31. Holleran, et al., 1993, "Processing of Epidermal Glucosylceramides is required for optimal mammalian cutaneous permeability barrier function," Jrnl of Clinical Investiations, 91:1656-1664.
- _____ 32. Holleran et al., 1997, "Structural and biochemical basis for the UVB-induced alterations in epidermal barrier function," Photoderm. Photoimmunol. Photomed., 13:117-128.
- _____ 33. Hsu et al., 1997, "Effects of oleanolic acid and ursolic acid on inhibiting tumor growth and enhancing the recovery of hematopoietic system postirradiation in mice," Cancer Lett., 111:7-13.
- _____ 34. Huang et al., 1994, " Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid," Cancer Res., 54:701-708.
- _____ 35. Kennedy et al., 1996, "Stratum corneum lipids of human epidermal keratinocyte air-liquid cultures: implications for barrier function," Pharmaceut. Res., 13:1162-1167.
- _____ 36. Kligman et al., 1993, "Treatment of photoaged skin with topical tretinoin," Skin Pharmacol., 6(Suppl.1):78-82.

- _____ 37. Liposome Technology, Gregory Gregoriadis editor, CRC Press Inc., Boca Raton, Florida, 1984, 29-35, 37-49, 68-107.
- _____ 38. Liu, J., 1995, "Pharmacology of oleanolic acid and ursolic acid," J. Ethnopharmacol., 49:57-68.
- _____ 39. Manez et al., 1997, "Effect of selected triterpenoids on chronic dermal inflammation," Eur. J. Pharmacol., 334:103-105.
- _____ 40. Mezzetti et al., 1971, "Chemistry of urosolic acid," Planta Med., 20:244-252.
- _____ 41. Najid et al., 1992, "Characterization of ursolic acid as a lipoxygenase and cyclooxygenase inhibitor using macrophages, platelets and differentiated HL60 leukemic cells," FEBS, 299:213-217.
- _____ 42. Nishimori et al., "A new approach for the improvement of photoaged skin through collagen fiber bundle reconstruction," Proceedings of the 20th IFSCC Congress, Cannes, France, September 14-19, 1998, 1-21.
- _____ 43. Paik et al., 1998, "Induction of differentiation of the cultured rat mammary epithelial cells by triterpene acids," Arch. Pharm. Res., 21:398-405.
- _____ 44. Parker, M., "Design and assessment of preservative systems for cosmetics," Cosmetic and Drug Preservation. Principles and Practices, J.J. Kabara editor, Marcel Dekker, New York, 1984, 389-402.
- _____ 45. Ponc et al., 1997, "The formation of competent barrier lipids in reconstructed human epidermis requires the presence of Vitamin C," J. Invest. Dermatol., 109:348-355.
- _____ 46. Ponc et al., 1990, "Retinoids and lipid changes in keratinocytes," Meth. Enzymol., 190:30-41.

- _____ 47. Robert et al., 1999, "Harmful effects of UVA on the structure and barrier function of engineered human cutaneous tissues," Int. J. Radiat. Biol., 75:317-326.
- _____ 48. Rogers et al., 1996, "Stratum corneum lipids: the effect of ageing and the seasons," Arch. Dermatol. Res., 288:765-770.
- _____ 49. Schaefer H. and Redelmeier, T., 1996, Skin Barrier: Principles of Percutaneous Absorption, Karger, Basel, Switzerland, 1-42.
- _____ 50. Suh et al., 1998, "Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages," Cancer Res., 58:717-723.
- _____ 51. Suh et al., 1999, "A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxolean-1,9-dien-28-oic acid, with potent differentiation, antiproliferative, and anti-inflammatory activity," Cancer Res., 59:336-341.
- _____ 52. Swartzendruber et al., 1987, "Evidence that the corneocyte has a chemically bound lipid envelope," J. Invest. Dermatol., 88:709-713.
- _____ 53. Tokuda et al., 1986, "Inhibitory effects of ursolic and oleanolic acid on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate," Cancer Lett., 33:279-285.
- _____ 54. Varila et al., 1995, "The effect of topical oestradiol on skin collagen of postmenopausal women," British Journal of Obstetrics and Gynaecology, 102:985-989.
- _____ 55. Wefers et al., 1991, "Influence of UV irradiation on the composition of human stratum corneum lipids," J. Invest. Dermatol., 96:959-962.
- _____ 56. Ying et al., 1991, "Inhibition of human leucocyte elastase by ursolic acid," Biochem. J., 277:521-526.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David A. Brown and Daniel B. Yarosh
Serial No. : 10/070,466
Filed : March 7, 2002
For : COMPOSITIONS AND METHODS FOR
MODIFICATION OF SKIN LIPID CONTENT
Examiner : R. Cook
Group : 1614

SUPPLEMENTAL MODIFIED 1449 FORMFOREIGN PATENT DOCUMENTS

<u>Examiner Initial</u>		<u>Document Number</u>	<u>Date</u>	<u>Country</u>
_____	57.	2 723 313	8/1994	France

OTHER ART

<u>Examiner Initial</u>		
_____	58.	FreeTranslation.com's computer-generated English language translation of FR 2 723 313 (Reference 57 above).
_____	59.	WorldLingo.com's computer-generated English language translation of FR 2 723 313 (Reference 57 above).